Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

DiNardo

Showing results (1111-1120 of 1,482) with videos related to

Pageof 149
Sort By:
Blood Advances|May 8, 2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLSung Choe, Hongfang Wang, Courtney D DiNardo, et al.
Blood|June 8, 2017
Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.
Nature Communications|October 22, 2020
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomicsKiyomi Morita, Feng Wang, Katharina Jahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2025
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AMLCourtney D DiNardo, Jennifer Marvin-Peek, Sanam Loghavi, et al.
Nature Communications|November 20, 2020
Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomicsKiyomi Morita, Feng Wang, Katharina Jahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2026
The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)Ghayas C Issa, Branko Cuglievan, Georgina El Hajjar, et al.
Blood|December 5, 2018
Molecular remission and response patterns in patients with mutant-<i>IDH2</i> acute myeloid leukemia treated with enasidenibEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 25, 2024
Clinical-Hematological Changes and Predictors of Severity in Acute Food Protein-Induced Enterocolitis Syndrome Reactions at Oral Food Challenge: A Multicenter Observational StudyL Argiz, M Valsami-Fokianos, S Arasi, et al.
Blood|October 7, 2020
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 studyEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Leukemia|December 3, 2025
DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective studyCarmelo Gurnari, Hideki Makishima, Arda Durmaz, et al.
Pageof 149

Showing results (1111-1120 of 1,482) with videos related to

Sort By:
Pageof 149
Blood Advances|May 8, 2020
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AMLSung Choe, Hongfang Wang, Courtney D DiNardo, et al.
Blood|June 8, 2017
Enasidenib in mutant <i>IDH2</i> relapsed or refractory acute myeloid leukemiaEytan M Stein, Courtney D DiNardo, Daniel A Pollyea, et al.
Nature Communications|October 22, 2020
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomicsKiyomi Morita, Feng Wang, Katharina Jahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 13, 2025
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AMLCourtney D DiNardo, Jennifer Marvin-Peek, Sanam Loghavi, et al.
Nature Communications|November 20, 2020
Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomicsKiyomi Morita, Feng Wang, Katharina Jahn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2026
The All-Oral Combination of Revumenib, Decitabine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia (SAVE)Ghayas C Issa, Branko Cuglievan, Georgina El Hajjar, et al.
Blood|December 5, 2018
Molecular remission and response patterns in patients with mutant-<i>IDH2</i> acute myeloid leukemia treated with enasidenibEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 25, 2024
Clinical-Hematological Changes and Predictors of Severity in Acute Food Protein-Induced Enterocolitis Syndrome Reactions at Oral Food Challenge: A Multicenter Observational StudyL Argiz, M Valsami-Fokianos, S Arasi, et al.
Blood|October 7, 2020
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 studyEytan M Stein, Courtney D DiNardo, Amir T Fathi, et al.
Leukemia|December 3, 2025
DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective studyCarmelo Gurnari, Hideki Makishima, Arda Durmaz, et al.
Pageof 149